Share Email Print
cover

Proceedings Paper • new

Preliminary experiences of DBT (digital breast tomosynthesis) and hybrid 18F-FDG-PET/MR (PETMR) for neoadjuvant chemotherapy (NAC) cases in breast cancer
Author(s): Nachiko Uchiyama; Hiroaki Kurihara; Takayuki Kinoshita; Masayuki Yoshida; Mari Kikuchi; Kyoichi Otsuka; Yasuaki Arai
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Twenty-six patients with 27 invasive breast cancers were enrolled and MMG+DBT, US, and PETMR were obtained before and after NAC. The clinical response to chemotherapy was classified into the following categories, based on the RECIST and pathological response was classified in accordance with JBCS. Among Grade 3 (n=7), MMG+DBT demonstrated as CR by 71.4% and as PR by 28.6%. Among PR lesions, estimated pathological response was Grade 2 (n=2). PETMR demonstrated as PR by 57.1% and as CR by 42.9%. Among PR lesions, estimated pathological response was Grade 2 (n=4). FDG uptake was positive before and negative after NAC with all primary lesions. Among Grades 1b-2 (n=15), MMG +DBT demonstrated as PR by 76.3% (n=11) and four as CR by 26.7% (n=4). Among PR lesions, estimated pathological response were Grade 1b (n=5) and Grade 2 (n=6). PETMR demonstrated as PR by 80.0% and as CR by 20.0%. Among PR lesions, estimated pathological response were Grade 1b (n=3) and Grade 2 (n=9). After NAC, FDG uptake was positive in primary lesions by 20.0% (n=3). Among Grade 0-1a (n=5), MMG+DBT demonstrated as SD by 60.0 % and as PR by 40.0%. Among PR lesions, estimated pathological response were Grade 1b (n=1) and Grade 2 (n=1). PETMR demonstrated as SD by 40.0 % and as PR by 60.0%. Among PR lesions, estimated pathological response were Grade 1b (n=2) and Grade 2 (n=1). After NAC, FDG uptake was positive in primary lesions by 80.0% (n=4).

Paper Details

Date Published: 6 July 2018
PDF: 10 pages
Proc. SPIE 10718, 14th International Workshop on Breast Imaging (IWBI 2018), 107181O (6 July 2018); doi: 10.1117/12.2317675
Show Author Affiliations
Nachiko Uchiyama, National Cancer Ctr. (Japan)
Hiroaki Kurihara, National Cancer Ctr. (Japan)
Takayuki Kinoshita, National Cancer Ctr. (Japan)
Masayuki Yoshida, National Cancer Ctr. (Japan)
Mari Kikuchi, National Cancer Ctr. (Japan)
Kyoichi Otsuka, SIEMENS Healthcare (Japan)
Yasuaki Arai, National Cancer Ctr. (Japan)


Published in SPIE Proceedings Vol. 10718:
14th International Workshop on Breast Imaging (IWBI 2018)
Elizabeth A. Krupinski, Editor(s)

© SPIE. Terms of Use
Back to Top